Afexa Life Sciences Inc.
TSX : CVQ

Afexa Life Sciences Inc.

November 14, 2008 15:58 ET

News Conference Advisory: World's Top Cancer Research Body Sponsors Landmark Trial of COLD-FX for Leukemia Patients

U.S. Research Team to Consider its Cold/FluFighting Potential, Ability to Strengthen Immune System

EDMONTON, ALBERTA--(Marketwire - Nov. 14, 2008) - CV Technologies Inc. (TSX:CVQ) -



WHAT: News Conference to discuss details of landmark clinical trial of
COLD-FX's cold/flu fighting and immune strengthening properties for
chronic lymphocytic leukemia patients sponsored by U.S. National
Cancer Institute, a division of the National Institutes of Health.

WHO: - Dr. Kevin P. High, Principal Trial Investigator, Chief, Section on
Infectious Disease, Professor of Medicine, Sections on Infectious
Diseases Hematology/Oncology Wake Forest University School of
Medicine, Winston-Salem, North Carolina. (by teleconference)

- Dr. Sandra Miller, Department of Anatomy and Biology, Faculty of
Medicine, McGill University

- Dr. Jacqueline Shan, President and Chief Scientific Officer, CV
Technologies

- Dr. Sharla Sutherland, Vice President, Clinical and Regulatory
Affairs, CV Technologies

WHERE: # 9604-20th Avenue, Edmonton Research Park

WHEN: 10:00 MT, Monday, Nov 17, 2008


Note: COLD-FX Beta "B" roll available for TV reporters

Contact Information

  • CV Technologies Inc., Edmonton Research Park
    Warren Michaels
    Vice President, Communications
    (780) 432-0022